The delayed-start study in Parkinson disease: can't satisfy everyone.
Olanow
C Warren
CW
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA. Warren.olanow@mssm.edu
Rascol
O
O
D003627:Data Interpretation, Statistical; D004305:Dose-Response Relationship, Drug; D023381:Endpoint Determination; D006801:Humans; D007189:Indans / Q000008:administration & dosage; D018696:Neuroprotective Agents / Q000008:administration & dosage; D017063:Outcome Assessment, Health Care / Q000379:methods*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic / Q000379:methods* / Q000592:standards*; D015203:Reproducibility of Results; D012107:Research Design / Q000592:standards*; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome
D007189:Indans; D018696:Neuroprotective Agents; C031967:rasagiline